This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Implied Volatility Surging for Niagen Bioscience Stock Options
by Zacks Equity Research
Investors need to pay close attention to NAGE stock based on the movements in the options market lately.
NAGEPositive Net Change
biotechnology biotechs medical
Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's Q2 spotlight is on Skyrizi and Rinvoq as rising immunology sales aim to offset Humira's decline ahead of July 31 earnings.
ABBVPositive Net Change JNJPositive Net Change LLYPositive Net Change
biotechs earnings medical pharmaceuticals
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
by Zacks Equity Research
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
RHHBYPositive Net Change BMYPositive Net Change AMGNPositive Net Change NRIXPositive Net Change
biotechnology biotechs medical payments
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?
by Sundeep Ganoria
Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.
MRNANegative Net Change MRKPositive Net Change BNTXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?
by Ahan Chakraborty
NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
by Zacks Equity Research
United Therapeutics acquires Thymmune, adding preclinical thymic cell therapy THY-100 & expanding its regenerative medicine pipeline for organ transplantation.
UTHRPositive Net Change AMRNNegative Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechs
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?
by Kanishka Das
TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.
TGTXPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechs
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
by Zacks Equity Research
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
NVSPositive Net Change BAYRYNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Yutrepia Maintain Momentum for LQDA Stock in 2026?
by Ekta Bagri
LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and profitability as the company expands in PAH.
LQDAPositive Net Change JNJPositive Net Change UTHRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is AtaiBeckley Stock Worth Buying After Its Stronger Rally in 2026?
by Kanishka Das
ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.
ATAIPositive Net Change CMPSNegative Net Change GHRSPositive Net Change
biotechs